- IBD
-
Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
-
Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, Byong Duk Ye, Kyeong Ok Kim, Jeong Eun Shin, Yong Sik Yoon, Hong Sub Lee, Sung Hoon Jung, Miyoung Choi, Soo-Young Na, Chang Hwan Choi, Joo Sung Kim, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
-
Intest Res 2023;21(1):43-60. Published online October 18, 2022
-
DOI: https://doi.org/10.5217/ir.2022.00029
-
-
 Abstract
 PDF PubReader ePub
- Crohn’s disease (CD) is a relapsing and progressive condition characterized by diarrhea, abdominal pain, weight loss, and hematochezia that results in serious complications such as perforations, fistulas, and abscesses. Various medications, interventions, and surgical treatments have been used to treat CD. The Korean guidelines for CD management were distributed in 2012 and revised in 2017 by the Inflammatory Bowel Disease (IBD) Research Group of the Korean Association for the Study of Intestinal Diseases. Substantial progress in mucosal immunologic research has elucidated the pathophysiology of IBD, leading to development of biological agents for treatment of CD. The first developed biologic agent, tumor necrosis factor-α agents, were shown to be efficacious in CD, heralding a new era in management of CD. Subsequently, vedolizumab, a monoclonal antibody against integrin α4β7, and ustekinumab, a human monoclonal antibody that inhibits the common p40 subunit of interleukin-12 and interleukin-23, were both approved for clinical use and are efficacious and safe for both induction and maintenance of remission in moderate-to-severe CD patients. Moreover, a recent study showed the non-inferiority of CT-P13, an infliximab biosimilar, compared with infliximab in CD patients. The third Korean guidelines for CD management provide updated information regarding treatment of moderate-to-severe CD patients with biologic agents.
-
Citations
Citations to this article as recorded by  - One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study
Chang Kyun Lee, Won Moon, Jaeyoung Chun, Eun Soo Kim, Hyung Wook Kim, Hyuk Yoon, Hyun Soo Kim, Yoo Jin Lee, Chang Hwan Choi, Yunho Jung, Sung Chul Park, Geun Am Song, Jong Hun Lee, Eun Suk Jung, Youngdoe Kim, Su Young Jung, Jong Min Choi, Byong Duk Ye
Inflammatory Bowel Diseases.2025; 31(5): 1306. CrossRef - Smoking Experience before Adulthood Is Associated with an Increased Risk of Developing Ulcerative Colitis in Adult Ex-Smokers
Yu Kyung Jun, Bongseong Kim, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Kyungdo Han, Hyuk Yoon
Yonsei Medical Journal.2025; 66(1): 9. CrossRef - Temporal trends in obesity and its prognostic impact in Korean patients with inflammatory bowel disease
Min Kyu Kim, Seung Hwan Shin, Cheol-Hyung Lee, Soyoung Kim, Jong Whan Kim, Songhyun Lee, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sung Wook Hwang
Journal of Gastroenterology.2025; 60(5): 583. CrossRef - Metabolic musculoskeletal disorders in patients with inflammatory bowel disease
Young Joo Yang, Seong Ran Jeon
The Korean Journal of Internal Medicine.2025; 40(2): 181. CrossRef - IFN-γ-Induced intestinal epithelial cell-type-specific programmed cell death: PANoptosis and its modulation in Crohn’s disease
Chansu Lee, Ji Eun Kim, Yeo-Eun Cha, Ji Hwan Moon, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim, Sung Noh Hong
Frontiers in Immunology.2025;[Epub] CrossRef - Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
Gut and Liver.2025; 19(3): 376. CrossRef - Impact of early aggressive treatment on long-term biochemical marker patterns in inflammatory bowel disease
Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Soyeon Ahn, Hyuk Yoon
Journal of Gastroenterology.2025;[Epub] CrossRef - Optimizing Infliximab Use in Real-World Inflammatory Bowel Disease: Insights from a Population Pharmacokinetic Model Integrating Intravenous and Subcutaneous Formulations
Sung Hoon Jung, Sang-Bum Kang
Gut and Liver.2025; 19(3): 299. CrossRef - Herpes zoster infection in patients with inflammatory bowel disease
Dong Hyun Kim, Sang-Bum Kang
The Korean Journal of Internal Medicine.2025; 40(3): 347. CrossRef - Annual Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease During Infliximab Maintenance Therapy: Balancing Efficacy with Risk of Pharmacokinetic Failure
Yujin Lim, Boram Park, Kyeongman Jeon, Ok Soon Jeong, Eun Ran Kim, Young-Ho Kim, Dong Kyung Chang, Sung Noh Hong
Digestive Diseases and Sciences.2025;[Epub] CrossRef - Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
Ji Young Chang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon, Jihye Park
Journal of Gastroenterology and Hepatology.2024; 39(3): 519. CrossRef - Factors Associated with Reaching Mid-Parental Height in Patients Diagnosed with Inflammatory Bowel Disease in Childhood and Adolescent Period
So Yoon Choi, Sujin Choi, Byung-Ho Choe, Jae Hong Park, Kwang-Hae Choi, Hae Jeong Lee, Ji Sook Park, Ji-Hyun Seo, Jae Young Kim, Hyo-Jeong Jang, Suk Jin Hong, Eun Young Kim, Yeoun Joo Lee, Ben Kang
Gut and Liver.2024; 18(1): 106. CrossRef - Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease
Yoo Min Lee, Eun Sil Kim, Sujin Choi, Hyo-Jeong Jang, Yu Bin Kim, So Yoon Choi, Byung-Ho Choe, Ben Kang
Gut and Liver.2024; 18(3): 498. CrossRef - Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients
Ga Hee Kim, Minjun Kim, Kyuwon Kim, Jung-Bin Park, Ji Eun Baek, June Hwa Bae, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Yonsei Medical Journal.2024; 65(5): 276. CrossRef - Optimal Treatment Approaches to Intestinal Behçet's Disease Complicated by Myelodysplastic Syndrome: The KASID and KSBD Multicenter Study
Jung-Bin Park, So Jung Han, Seung Bum Lee, Dong Hyun Kim, Jae Hee Cheon, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Soo Jung Park, Sang Hyoung Park
Yonsei Medical Journal.2024; 65(5): 265. CrossRef - Self-screening questionnaire for perianal fistulizing disease in patients with Crohn’s disease
O Seong Kweon, Ben Kang, Yoo Jin Lee, Eun Soo Kim, Sung Kook Kim, Hyun Seok Lee, Yun Jin Chung, Kyeong Ok Kim, Byung Ik Jang
The Korean Journal of Internal Medicine.2024; 39(3): 430. CrossRef - Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray Barclay, Tomoyuki Mizuno, Iris K. Minichmayr, Ron J. Keizer, Sebastian G. Wicha, Gertjan Wolbink, Jo Lambert, Séverine Vermeire, Annick de Vries, Konstantinos Papamichael,
Therapeutic Drug Monitoring.2024; 46(3): 291. CrossRef - Development and Assessment of a Novel Ulcerative Colitis–Specific Quality of Life Questionnaire: A Prospective, Multi-Institutional Study
Jihye Park, Hyun-Soo Zhang, Chung Mo Nam, Joo Sung Kim, Young-Ho Kim, Dong Il Park, Byong Duk Ye, Yoon Tae Jeen, Sehyun Kim, Jae Hee Cheon
Yonsei Medical Journal.2024; 65(11): 636. CrossRef - Clinical Significance of Prognostic Nutrition Index in Patients with Crohn’s Disease after Primary Bowel Resection
Hyeon Woo Bae, Yong Joon Lee, Min Young Park, Seung Yoon Yang, Yoon Dae Han, Min Soo Cho, Hyuk Hur, Kang Young Lee, Jae Hee Cheon, Joseph C. Carmichael, Byung Soh Min
Yonsei Medical Journal.2024; 65(7): 380. CrossRef - Advancements in Targeted Therapies for the Management of Crohn’s Disease: A Comprehensive Review
Peter Girgis, Tanisha LNU, Amna Ahmad, Mina Daniel, Maria Kamel, Jade L Gambill, Atika Shahzadi, Usman Khan, Anam Zara, Vagisha Sharma
Cureus.2024;[Epub] CrossRef - Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure
June Hwa Bae, Jung-Bin Park, Ji Eun Baek, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sung Wook Hwang
Gut and Liver.2024; 18(4): 667. CrossRef - Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Jia-Feng Wu, Hsu-Heng Yen, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin
Intestinal Research.2024; 22(3): 250. CrossRef - Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study
Min Jee Kim, Ye-Jee Kim, Daehyun Jeong, Seonok Kim, Seokchan Hong, Sang Hyoung Park, Kyung-Wook Jo
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef - Prevalence and risk factors for gallstone and renal stone formation in patients with intestinal Behçet’s disease
Jaewon Song, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2024; 39(5): 770. CrossRef - Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn’s disease patients: a retrospective multicenter study
Ji Eun Na, Yong Eun Park, Jongha Park, Tae-Oh Kim, Jong Hoon Lee, Su Bum Park, Soyoung Kim, Seung Bum Lee
BMC Gastroenterology.2024;[Epub] CrossRef - Effectiveness of Early Thiopurine Use in Korean Patients With Moderate-to-Severe Ulcerative Colitis
Hye Kyung Hyun, Ji Won Kim, Jun Lee, Yoon Tae Jeen, Tae-Oh Kim, Joo Sung Kim, Jae Jun Park, SungNoh Hong, Dong Il Park, Hyun-Soo Kim, YooJin Lee, Eun Suk Jung, Youngdoe Kim, Su Young Jung, Jae Hee Cheon
Journal of Clinical Gastroenterology.2024;[Epub] CrossRef - Characteristics and Treatment Outcomes of Transition among Patients with Inflammatory Bowel Disease
Eun Jin Yoo, Sang-Hoon Cho, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Yonsei Medical Journal.2023; 64(9): 541. CrossRef - Effectiveness and tolerability of methotrexate monotherapy in Crohn’s disease patients: a multicenter observational study
Jihye Park, Jaeyoung Chun, Soo Jung Park, Jae Jun Park, Tae Il Kim, Hyuk Yoon, Jae Hee Cheon
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef - Combination therapy of ustekinumab and immunomodulator for inflammatory bowel disease: concerns about the different results observed between two meta‐analyses
T Yoshihara, S Shinzaki, H Iijima, Y Tsujii, Y Hayashi, T Takehara
Journal of Gastroenterology and Hepatology.2023; 38(5): 830. CrossRef - Safety of Biologic Therapy in Older Adults with Inflammatory Bowel Diseases
Tae-Geun Gweon
The Korean Journal of Gastroenterology.2023; 81(5): 230. CrossRef - Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea
Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
Frontiers in Medicine.2023;[Epub] CrossRef - How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
Jihye Park
Intestinal Research.2023; 21(3): 275. CrossRef - 10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification – a nationwide population-based study
Hee Moon Koo, Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Young Kee Shin, Hyuk Yoon
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef - Enrichment of Activated Fibroblasts as a Potential Biomarker for a Non-Durable Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn’s Disease
Soo-Kyung Park, Gi-Young Lee, Sangsoo Kim, Chil-Woo Lee, Chang-Hwan Choi, Sang-Bum Kang, Tae-Oh Kim, Jaeyoung Chun, Jae-Myung Cha, Jong-Pil Im, Kwang-Sung Ahn, Seon-Young Kim, Min-Suk Kim, Chang-Kyun Lee, Dong-Il Park
International Journal of Molecular Sciences.2023; 24(19): 14799. CrossRef - Evaluation of Bacterial and Fungal Biomarkers for Differentiation and Prognosis of Patients with Inflammatory Bowel Disease
Hyuk Yoon, Sunghyouk Park, Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee
Microorganisms.2023; 11(12): 2882. CrossRef
-
7,133
View
-
522
Download
-
34
Web of Science
-
35
Crossref
|
KASID
